Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

AIMS: Heart failure (HF) and type 2 diabetes (T2D), common co‐morbidities, translate into worse patient prognoses and higher direct costs than for either condition alone. Empagliflozin has been shown to markedly reduce cardiovascular (CV) deaths and HF hospitalizations (HHF) in HF patients with T2D....

Descripción completa

Detalles Bibliográficos
Autores principales: Reifsnider, Odette S., Kansal, Anuraag R., Franke, Jennifer, Lee, Joseph, George, Jyothis T., Brueckmann, Martina, Kaspers, Stefan, Brand, Sarah B., Ustyugova, Anastasia, Linden, Stephan, Stargardter, Matthew, Hau, Nikco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754962/
https://www.ncbi.nlm.nih.gov/pubmed/32909680
http://dx.doi.org/10.1002/ehf2.12985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754962/
https://www.ncbi.nlm.nih.gov/pubmed/32909680
http://dx.doi.org/10.1002/ehf2.12985

Ejemplares similares